Biotech Values

[jbog]

Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis

“Novartis notified Enanta that as part of an ongoing portfolio transformation, HCV research would no longer be a strategic focus for Novartis,” stated Jay R. Luly, Ph.D., President and CEO. “We appreciate Novartis’ contributions to the clinical development of EDP-239 and its ready agreement to return the NS5A program to us. Enanta is now positioned with three wholly-owned HCV programs from which future drug combinations can be explored.”

http://finance.yahoo.com/news/enanta-regains-full-rights-ns5a-120000172.html